Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 26 articles: HTML format

Single Articles

November 2023
1. VON KODOLITSCH Y, Kubisch C, Carrel T
   AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
   Lancet. 2023;402:1626.
   PubMed    
   
   
   
2. KUEPPERS F
   AATD as a genetic risk factor for aneurysmal disease.
   Lancet. 2023;402:1625-1626.
   PubMed    
   
   
   October 2023
3. VOGEL A, Meyer T, Saborowski A
   IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
   Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
   PubMed    
   
   
   
4. QIN S, Chen M, Cheng AL, Kaseb AO, et al
   Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
   Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
   PubMed     Abstract available
   
   
   September 2023
5. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
   The price and value of therapeutic synergy in liver cancer.
   Lancet. 2023;402:1108-1110.
   PubMed    
   
   
   
6. TAPPER EB, Serper M
   Screening for advanced liver disease in the general population.
   Lancet. 2023;402:941-943.
   PubMed    
   
   
   
7. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
   Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
   Lancet. 2023;402:988-996.
   PubMed     Abstract available
   
   
   August 2023
8. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
   Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
   Lancet. 2023;402:e10.
   PubMed    
   
   
   July 2023
9. QIN S, Chan SL, Gu S, Bai Y, et al
   Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
   Lancet. 2023 Jul 24:S0140-6736(23)00961-3. doi: 10.1016/S0140-6736(23)00961.
   PubMed     Abstract available
   
   
   May 2023
10. ADAMS PC, Jeffrey G, Ryan J
    Haemochromatosis.
    Lancet. 2023;401:1811-1821.
    PubMed     Abstract available
    
    
    April 2023
11. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    PubMed    
    
    
    
12. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available
    
    
    February 2023
13. ALLISON MED, Verne J, Bernal W, Clayton M, et al
    Deaths from alcohol-related liver disease in the UK: an escalating tragedy.
    Lancet. 2023;401:418-420.
    PubMed    
    
    
    September 2022
14. VOGEL A, Meyer T, Sapisochin G, Salem R, et al
    Hepatocellular carcinoma.
    Lancet. 2022 Sep 6. pii: S0140-6736(22)01200.
    PubMed     Abstract available
    
    
    January 2022
15. COOKE GS, Nayagam S
    Liver disease: at the heart of public health challenges for Europe in the 21st century.
    Lancet. 2022;399:9-10.
    PubMed    
    
    
    
16. KLEINERT S, Horton R
    An urgent challenge for Europe: from tackling liver diseases to protecting liver health.
    Lancet. 2022;399:7-9.
    PubMed    
    
    
    December 2021
17. NHLANE R, Kreuels B, Mallewa J, Chetcuti K, et al
    Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B.
    Lancet. 2021;398:2288.
    PubMed    
    
    
    
18. WATTS G
    Tom Hemming Karlsen: hepatologist with a public health message.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)02746.
    PubMed    
    
    
    
19. KARLSEN TH, Sheron N, Zelber-Sagi S, Carrieri P, et al
    The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)01701.
    PubMed    
    
    
    October 2021
20. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    PubMed     Abstract available
    
    
    
21. KRIEGERMEIER A, Taylor S
    Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome.
    Lancet. 2021;398:1544-1545.
    PubMed    
    
    
    September 2021
22. GINES P, Krag A, Abraldes JG, Sola E, et al
    Liver cirrhosis.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)01374.
    PubMed     Abstract available
    
    
    
23. GURNARI C, Colak C, Zawit M, Maciejewski JP, et al
    Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria.
    Lancet. 2021;398:e14.
    PubMed    
    
    
    August 2021
24. TIAN M, Zhang Z, Yuan Y
    When a young hepatobiliary surgeon faces his own liver lesions diagnosis.
    Lancet. 2021;398:746.
    PubMed    
    
    
    April 2021
25. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    PubMed     Abstract available
    
    
    March 2021
26. WILLIAMS R, Alessi C, Alexander G, Allison M, et al
    New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
    Lancet. 2021 Mar 10. pii: S0140-6736(20)32396.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.